Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China NT Pharma Group Co (HKSE:01011) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China NT Pharma Group Co EBITDA Margin % Related Terms
China NT Pharma Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China NT Pharma Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where China NT Pharma Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China NT Pharma Group Co (HKSE:01011) has a EBITDA Margin % of 32.02% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China NT Pharma Group Co and its competitors. According to the industry distribution chart, China NT Pharma Group Co ranks #707 out of 959 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is China NT Pharma Group Co's EBITDA Margin % too high?
China NT Pharma Group Co's current EBITDA Margin % is 32.02%. The Drug Manufacturers industry median EBITDA Margin % is 11.89. China NT Pharma Group Co's value of 32.02% is 169.3% above this industry median. Based on the distribution chart, China NT Pharma Group Co ranks #707 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China NT Pharma Group Co has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does China NT Pharma Group Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China NT Pharma Group Co ranks #707 out of 959 companies for EBITDA Margin %. This places China NT Pharma Group Co in the lower half of its industry. The industry median EBITDA Margin % is 11.89. China NT Pharma Group Co's value of 32.02% is 169.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China NT Pharma Group Co's current EBITDA Margin % of 32.02% is 169.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China NT Pharma Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China NT Pharma Group Co's current EBITDA Margin % is 32.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China NT Pharma Group Co stock overvalued right now?
China NT Pharma Group Co (HKSE:01011) has a current EBITDA Margin % of 32.02%. The current EBITDA Margin % is 32.02% and 169.3% above the Drug Manufacturers industry median of 11.89. China NT Pharma Group Co's overall GF Score™ is 1/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China NT Pharma Group Co (HKSE:01011), the current EBITDA Margin % is 32.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The Group's operations are regarded as having two operating and reportable segments, namely Agency Services and Healthcare Related Services. The company generates maximum of its revenue from Healthcare Related Services.
1GF Score
Get the complete analysis for HKSE:01011
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01011 has been successfully added to your 
